Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Valentina Guarneri, Federico Piacentini et al.|Journal of Clinical Oncology|2023Cited by 25
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective studyGrazia Arpino, Sabino De Placido, Stefania Russo et al.|Journal of Cancer Research and Clinical Oncology|2015Cited by 15